These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 21381234)
1. Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature. Hasni SA; Kunz D; Finzel K; Gruber BL Spine (Phila Pa 1976); 2010 Aug; 35(18):E904-7. PubMed ID: 21381234 [TBL] [Abstract][Full Text] [Related]
2. Refractory vertebral sarcoidosis responding to infliximab. Garg S; Garg K; Altaf M; Magaldi JA J Clin Rheumatol; 2008 Aug; 14(4):238-40. PubMed ID: 18766126 [TBL] [Abstract][Full Text] [Related]
3. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report. Santos G; Sousa LE; João AM An Bras Dermatol; 2013; 88(6 Suppl 1):26-8. PubMed ID: 24346872 [TBL] [Abstract][Full Text] [Related]
4. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Baughman RP; Lower EE; Drent M Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Crommelin HA; van der Burg LM; Vorselaars AD; Drent M; van Moorsel CH; Rijkers GT; Deneer VH; Grutters JC Respir Med; 2016 Jun; 115():72-7. PubMed ID: 27215507 [TBL] [Abstract][Full Text] [Related]
6. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Thielen AM; Barde C; Saurat JH; Laffitte E Dermatology; 2009; 219(1):59-62. PubMed ID: 19468200 [TBL] [Abstract][Full Text] [Related]
7. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Milman N; Graudal N; Loft A; Mortensen J; Larsen J; Baslund B Clin Respir J; 2012 Oct; 6(4):238-47. PubMed ID: 22128762 [TBL] [Abstract][Full Text] [Related]
9. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334 [TBL] [Abstract][Full Text] [Related]
10. Osseous spinal sarcoidosis: an unusual but important entity to remember. Zubairi AB; Sheerani M; Haque AS; Ahsan H; Fatima K BMJ Case Rep; 2010 Nov; 2010():. PubMed ID: 22798517 [TBL] [Abstract][Full Text] [Related]
11. TNF inhibitor treating osseous sarcoidosis and dactylitis: case and literature review. Alawneh D; Al-Shyoukh A; Edrees A Clin Rheumatol; 2020 Jul; 39(7):2219-2222. PubMed ID: 32020444 [TBL] [Abstract][Full Text] [Related]
12. Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study. Lahmer T; Knopf A; Lanzl I; Heemann U; Thuermel K Rheumatol Int; 2012 Aug; 32(8):2367-70. PubMed ID: 21644042 [TBL] [Abstract][Full Text] [Related]
13. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Drent M; Cremers JP; Jansen TL; Baughman RP Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):91-107. PubMed ID: 25078637 [TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. Heidelberger V; Ingen-Housz-Oro S; Marquet A; Mahevas M; Bessis D; Bouillet L; Caux F; Chapelon-Abric C; Debarbieux S; Delaporte E; Duval-Modeste AB; Fain O; Joly P; Marchand-Adam S; Monfort JB; Noël N; Passeron T; Ruivard M; Sarrot-Reynauld F; Verrot D; Bouvry D; Fardet L; Chosidow O; Sève P; Valeyre D JAMA Dermatol; 2017 Jul; 153(7):681-685. PubMed ID: 28564695 [TBL] [Abstract][Full Text] [Related]
17. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital]. Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230 [TBL] [Abstract][Full Text] [Related]
18. TNF-α: a treatment target or cause of sarcoidosis? Amber KT; Bloom R; Mrowietz U; Hertl M J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2104-11. PubMed ID: 26419478 [TBL] [Abstract][Full Text] [Related]
19. [TNFα blocking agents and sarcoidosis: an update]. Toussirot E; Pertuiset E Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487 [TBL] [Abstract][Full Text] [Related]
20. Anti-TNF therapeutics for the treatment of sarcoidosis. Crommelin HA; Vorselaars AD; van Moorsel CH; Korenromp IH; Deneer VH; Grutters JC Immunotherapy; 2014; 6(10):1127-43. PubMed ID: 25428650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]